Ventricular Tachycardia or Ventricular Fibrillation or Death 2 years of follow-up on average [clinicaltrials_resource:d291a8baf7e74df9421773259003af18]
Primary endpoint of the study will be defined as a composite endpoint consisting of Ventricular Tachycardia or Ventricular Fibrillation requiring ATP therapy, ICD shock, or death, whichever occurs first
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Ventricular Tachycardia or Ventricular Fibrillation or Death 2 years of follow-up on average [clinicaltrials_resource:d291a8baf7e74df9421773259003af18]
Primary endpoint of the study will be defined as a composite endpoint consisting of Ventricular Tachycardia or Ventricular Fibrillation requiring ATP therapy, ICD shock, or death, whichever occurs first
Bio2RDF identifier
d291a8baf7e74df9421773259003af18
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d291a8baf7e74df9421773259003af18
measure [clinicaltrials_vocabulary:measure]
Ventricular Tachycardia or Ventricular Fibrillation or Death
time frame [clinicaltrials_vocabulary:time-frame]
2 years of follow-up on average
description
Primary endpoint of the study ...... death, whichever occurs first
identifier
clinicaltrials_resource:d291a8baf7e74df9421773259003af18
title
Ventricular Tachycardia or Ven ...... years of follow-up on average
@en
type
label
Ventricular Tachycardia or Ven ...... 1a8baf7e74df9421773259003af18]
@en